Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib

Authors :: Kevin F Chin
Timothy J. Yen
Vikram Bhattacharjee
Kayleigh C. Ross
Christopher D. Marion
Daehwan Kim
Source :: Oncotarget
Publication Year :: 2018
Publisher :: Impact Journals, LLC, 2018.
Abstract: Acquired resistance of metastatic melanoma (MM) tumors to BRAF V600E inhibitors (BRAFi’s) is commonplace in the clinic. Habitual relapse of patients contributes to

Full Text Access

Tools